The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance

BJU International

Volumn 109, Issue 3, 2012, Pages 360-366

  Van Poppel, Hein ^a   Haese, Alexander ^b   Graefen, Markus ^b   De La Taille, Alexandre ^c   Irani, Jacques ^d   De Reijke, Theo ^e   Remzi, Mesut ^f   Marberger, Michael ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HENRI MONDOR HOSPITAL   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

active surveillance; Gleason score; PCA3; prostate biopsy; prostate cancer; significant cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; EUROPE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR GENE;

AGED; ANTIGENS, NEOPLASM; BIOPSY; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM GRADING; PATIENT SELECTION; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; REFERENCE VALUES; ROC CURVE;

EID: 84855921304     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10377.x     Document Type: Article

References (23)

1. Haese A, de la Taille A, Van Poppel H, et al,. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-8
2. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al,. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9 (Pubitemid 30004960)
3. PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-16 (Pubitemid 36741368)
4. Marks LS, Fradet Y, Deras IL, et al,. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-5 (Pubitemid 46428401)
5. Deras IL, Aubin SM, Blase A, et al,. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-92
6. de la Taille A, Irani J, Graefen M, et al,. The PCA3 assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness. Eur Urol Suppl 2010; 9: 53 (abstract n.61)
7. Groskopf J, Aubin SM, Reid MJ, et al,. Validation of the PCA3 molecular urine test for predicting repeat biopsy outcome in the placebo arm of the dutasteride REDUCE trial. Presented at the American Society of Clinical Oncology (ASCO) 2010 Genitourinary Cancers Symposium, 5-7 March 2010, San Francisco, California, USA.
8. Crawford ED, Trabulsi EJ, Qian J, et al,. PCA3: a urine-based genetic assay for detection of prostate cancer in men with elevated PSA. J Urol 2010; 183 (Suppl. 4): e818 (abstract n. 2105)
9. Tombal B,. Over- and underdiagnosis of prostate cancer: the dangers. Eur Urol Suppl 2006; 5: 511-3 (Pubitemid 43374659)
10. Surveillance, Epidemiology and End Results. SEER Stat Fact Sheets: Prostate. Available at:. Accessed May 2011
11. Joniau S, Van Poppel H,. Localized prostate cancer: can we better define who is at risk of unfavourable outcome? BJU Int 2008; 101 (Suppl. 2): 5-10 (Pubitemid 351327276)
12. TM database. J Urol 2008; 180: 1330-4
13. Nakanishi H, Groskopf J, Fritsche HA, et al,. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 1804-9
14. Whitman EJ, Groskopf J, Ali A, et al,. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008; 180: 1975-8
15. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, et al,. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008; 68: 1215-22
16. Tosoian JJ, Loeb S, Kettermann A, et al,. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010; 183: 534-8
17. Hessels D, van Gils MP, van Hooij O, et al,. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010; 70: 10-6
18. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74 (Pubitemid 24037911)
19. Bastian PJ, Mangold LA, Epstein JI, Partin AW,. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004; 101: 2001-5 (Pubitemid 39425375)
20. Ochiai A, Troncoso P, Chen ME, Lloreta J, Babaian RJ,. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. J Urol 2005; 174: 2164-8 (Pubitemid 41611765)
21. Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H,. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy [see comments]. J Urol 2000; 163: 174-8
22. Noguchi M, Stamey TA, McNeal JE, Yemoto CM,. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001; 166: 104-9 (Pubitemid 32565354)
23. Chun FK, Briganti A, Shariat SF, et al,. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int 2006; 98: 329-34